Michael P Link, MD
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Link’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence G30861 · Current
Licensed to practise in California · since 1975 · expires 2029-01-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$5,818 in 2024
Medicaid paid $5,818 for 113 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 113 | $5,818 |
| 2024 | 113 | 1 | 18 | $5,818 |
| 2021 | 37 | 1 | 12 | $2,520 |
| 2018 | 45 | 1 | 12 | $2,460 |
See the largest Medicaid services in earlier years
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 37 | $2,520 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 45 | $2,460 |
Money from drug and device companies
$13,216 in 2025
| 2025 | 2 | 7 | $11,850 | $13,216 |
| 2022 | 2 | 2 | $3,973 | $3,973 |
| 2021 | 3 | 4 | $9,520 | $9,635 |
| 2020 | 2 | 4 | $5,763 | $5,763 |
| 2019 | 2 | 27 | $4,028 | $4,648 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | None | $6,714 | 2 payments
|
| Janssen Research & Development | Darzalex | $6,502 | 5 payments
|
See all 7 published payments
| GlaxoSmithKline | Travel · 2025-09-10 | None | $964 |
| GlaxoSmithKline | Consulting · 2025-09-10 | None | $5,750 |
| Janssen Research & Development | Consulting · 2025-03-28 | Darzalex | $6,100 |
| Janssen Research & Development | Meals · 2025-03-13 | Darzalex | $13 |
| Janssen Research & Development | Meals · 2025-03-13 | Darzalex | $37 |
| Janssen Research & Development | Meals · 2025-03-13 | Darzalex | $38 |
| Janssen Research & Development | Travel · 2025-02-18 | Darzalex | $314 |
See earlier years (2022, 2021, 2020, 2019)
2022: $3,973
| BeiGene USA | None | $3,500 | 1 payment
|
| Incyte | Jakafi | $473 | 1 payment
|
2021: $9,635
| Incyte | Jakafi | $5,020 | 2 payments
|
| Blueprint Medicines | None | $4,500 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $115 | 1 payment
|
2020: $5,763
| GlaxoSmithKline | None | $4,750 | 1 payment
|
| Incyte | Jakafi | $1,013 | 3 payments
|
2019: $4,648
| Eli Lilly and | None | $3,771 | 24 payments
|
| Incyte | None | $878 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Seagen Inc. · Pediatric Classical Hodgkin Lymphoma Consortium Study: Chod17 · 2020 | Their institution | $796,000 |
| Seagen Inc. · Pediatric Classical Hodgkin Lymphoma Consortium Study: Chod17 · 2021 | Their institution | $535,620 |
| Janssen Research & Development, LLC · A Randomized Open Label Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed Or Refractory Mature Bcell Non Hodgkin Lymphoma · 2021 | Their institution | $92,288 |
| Janssen Research & Development, LLC · A Randomized, Open-Label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed Or Refractory Mature B-Cell Non-Hodgkin Lymphoma · 2019 | Their institution | $3,328 |
| Janssen Research & Development, LLC · A Randomized, Open-Label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed Or Refractory Mature B-Cell Non-Hodgkin Lymphoma · 2020 | Their institution | $2,880 |
Professional record
- NPI
- 1982742862
- Licence
- CA G30861California G30861: Current · expires 2029-01-31
- Trained
- Stanford University School of Medicine, 1974
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 1000 Welch Rd, Suite 300, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-02
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.